Illumina Accelerator
VC Fund
San Francisco, United States
Illumina Accelerator is a VC fund in San Francisco focused on Biotechnology and Health Care. At Illumina, we’re committed to unlocking the power of the genome, and we know we can’t do it alone. Illumina Accelerator is our way of accelerating innovation in the entrepreneurial community. With extensive mentorship, financial support, and access to sequencing systems, reagents, and lab space, we’ve created a dynamic genomic ecosystem to helpstartups launch. Together we’ll advance the solutions that will transform medicine and improve human health and beyond.
- Total investments:
- 57
- Last investment:
- Lead investor:
- 77%
- Fund size:
- $40M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Illumina Accelerator invests in
Stages Illumina Accelerator invests in
Countries Illumina Accelerator invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amanda Cashin
|
|||
Charles Dadswell
|
|||
Marc Stapley
|
|||
|
Omead Ostadan
|
|||
|
Richard Klausner
|
Investment Focus
Industry
- Biotechnology 33 (58%)
- Health Care 16 (28%)
- Therapeutics 10 (18%)
- Bioinformatics 6 (11%)
- Health Diagnostics 6 (11%)
Stage
- Seed 19 (33%)
- Non-equity Assistance 12 (21%)
- Convertible Note 8 (14%)
- Pre-Seed 3 (5%)
- Venture - Series Unknown 1 (2%)
Country
- United States 21 (37%)
- United Kingdom 6 (11%)
- Israel 3 (5%)
- India 1 (2%)
- Canada 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Amanda Cashin
Co-Founder & Global Head of Illumina For Startups & Illumina Accelerator
|
Co-Founder & Global Head of Illumina For Startups & Illumina Accelerator | Total investments: 31 | Find email | |
|
Charles Dadswell
Senior Vice President & General Counsel
|
Senior Vice President & General Counsel | Total investments: 0 | Find email | |
|
Marc Stapley
Executive Vice President, Chief Administrative Officer, and Chief Financial Officer
|
Executive Vice President, Chief Administrative Officer, and Chief Financial Officer | Total investments: 0 | Find email | |
|
Omead Ostadan
Executive Vice President, Operations, Products & Strategy
|
Executive Vice President, Operations, Products & Strategy | Total investments: 0 | Find email | |
|
Richard Klausner
Chief Medical Officer & Interim General Manager, Oncology
|
Chief Medical Officer & Interim General Manager, Oncology | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Juno Bio
|
Juno Bio uses machine learning and state of the art bioinformatics to analyse and predict how best to manipulate microbiomes, significantly reducing the time and resources needed to improve their functionality. | $3.8M / Venture - Series Unknown / Jul 16, 2026 | |
Viridian Seeds
|
Viridian Seeds creates super-legumes to provide a sustainable source of healthy, nutritious plant proteins. | Seed / Sep 14, 2022 | |
|
Viridian Seeds
|
Viridian Seeds creates super-legumes to provide a sustainable source of healthy, nutritious plant proteins. | Seed / Sep 14, 2022 | |
|
Pandora Biosciences
|
Pandora Biosciences operates as a neuroscience company. | Non-equity Assistance / Sep 14, 2022 | |
|
Pandora Biosciences
|
Pandora Biosciences operates as a neuroscience company. | Non-equity Assistance / Sep 14, 2022 | |
Terrapeutics Pharma
|
Terrapeutics Pharma develops a drug discovery platform that is based on a groundbreaking technology. | Non-equity Assistance / Sep 14, 2022 | |
|
Terrapeutics Pharma
|
Terrapeutics Pharma develops a drug discovery platform that is based on a groundbreaking technology. | Non-equity Assistance / Sep 14, 2022 | |
|
Acrobat Genomics
|
Acrobat Genomics uses its unique high-throughput CRISPR gene editing precision technology to create a pipeline of new therapies. | Non-equity Assistance / Sep 14, 2022 | |
|
Acrobat Genomics
|
Acrobat Genomics uses its unique high-throughput CRISPR gene editing precision technology to create a pipeline of new therapies. | Non-equity Assistance / Sep 14, 2022 | |
Dama Health
|
Dama Health offers insights into unique predispositions, efficacy, and side effect profiles. Dama Health uses genetic testing and an automated matching system to match individuals to the best options for their unique needs. | Non-equity Assistance / Sep 14, 2022 | |
| See all 57 investments → | |||
Co-Investors
First In Ventures
3 deals together
Axial VC
2 deals together
Hyphen Capital
2 deals together
Rhythm VC
2 deals together
Saba Investments
2 deals together
UpHonest Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Illumina Accelerator invest in?
Illumina Accelerator invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Non-equity Assistance stage. Most of the 57 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Illumina Accelerator?
Public channels for Illumina Accelerator include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Illumina Accelerator?
The team at Illumina Accelerator includes Amanda Cashin (Co-Founder & Global Head of Illumina For Startups & Illumina Accelerator), Charles Dadswell (Senior Vice President & General Counsel) and Marc Stapley (Executive Vice President, Chief Administrative Officer, and Chief Financial Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
